In a very recently published study of BCG-responder and nonresponder urothelial carcinoma in situ cases, no difference in terms of PD-L1 SP263 or SP142 clone expression between the BCG responder and BCG-unresponsive patient group was found, but PD-L1 22C3 clone expression of tumour cells was found to be increased in posttreatment biopsies of BCG unresponsive cases and it has been suggested that PD-L1 22C3 expression may identify CIS cases that fail the BCG therapy [27]. This evidence concerns the gene CD274 and in situ carcinoma.